Free Trial
NASDAQ:ALRN

Aileron Therapeutics (ALRN) Stock Price, News & Analysis

Aileron Therapeutics logo
$2.55 -0.21 (-7.61%)
(As of 10:09 AM ET)

About Aileron Therapeutics Stock (NASDAQ:ALRN)

Key Stats

Today's Range
$2.55
$2.73
50-Day Range
$2.65
$4.12
52-Week Range
$1.61
$7.42
Volume
16,180 shs
Average Volume
73,636 shs
Market Capitalization
$55.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.00
Consensus Rating
Strong Buy

Company Overview

Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.

Aileron Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
72nd Percentile Overall Score

ALRN MarketRank™: 

Aileron Therapeutics scored higher than 72% of companies evaluated by MarketBeat, and ranked 308th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Aileron Therapeutics has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Aileron Therapeutics has received no research coverage in the past 90 days.

  • Read more about Aileron Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Aileron Therapeutics are expected to grow in the coming year, from ($1.56) to ($1.41) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Aileron Therapeutics is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Aileron Therapeutics is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Aileron Therapeutics has a P/B Ratio of 1.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.19% of the float of Aileron Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Aileron Therapeutics has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Aileron Therapeutics has recently decreased by 8.72%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Aileron Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Aileron Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.19% of the float of Aileron Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Aileron Therapeutics has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Aileron Therapeutics has recently decreased by 8.72%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Aileron Therapeutics has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Aileron Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    Only 1 people have searched for ALRN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Aileron Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.10% of the stock of Aileron Therapeutics is held by insiders.

  • Percentage Held by Institutions

    90.89% of the stock of Aileron Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Aileron Therapeutics' insider trading history.
Receive ALRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aileron Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALRN Stock News Headlines

Aileron Therapeutics, Inc. (NASDAQ:ALRN) Sees Large Drop in Short Interest
Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners
The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…
See More Headlines

ALRN Stock Analysis - Frequently Asked Questions

Aileron Therapeutics' stock was trading at $3.05 at the start of the year. Since then, ALRN stock has decreased by 13.1% and is now trading at $2.65.
View the best growth stocks for 2024 here
.

Aileron Therapeutics, Inc. (NASDAQ:ALRN) posted its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by $0.20.

Aileron Therapeutics's stock reverse split before market open on Thursday, November 10th 2022. The 1-20 reverse split was announced on Thursday, November 10th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 10th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Aileron Therapeutics (ALRN) raised $61 million in an initial public offering on Thursday, June 29th 2017. The company issued 3,800,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Aileron Therapeutics' top institutional shareholders include Geode Capital Management LLC (1.06%), Sigma Planning Corp (0.98%) and KG&L Capital Management LLC (0.06%). Insiders that own company stock include Of Texas/Texas Am I University and James Brian Windsor.
View institutional ownership trends
.

Shares of ALRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aileron Therapeutics investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), AST SpaceMobile (ASTS), Virgin Galactic (SPCE) and Phunware (PHUN).

Company Calendar

Last Earnings
8/14/2024
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ALRN
Fax
N/A
Employees
9
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$19.00
High Stock Price Target
$19.00
Low Stock Price Target
$19.00
Potential Upside/Downside
+588.4%
Consensus Rating
Strong Buy
Rating Score (0-4)
3.50
Research Coverage
2 Analysts

Profitability

Net Income
$-15,730,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.41 per share

Miscellaneous

Free Float
20,561,000
Market Cap
$59.81 million
Optionable
Not Optionable
Beta
2.35
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:ALRN) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners